Immatics NV (IMTX)vsRevolution Medicines Inc (RVMD)
IMTX
Immatics NV
$8.79
+0.46%
HEALTHCARE · Cap: $1.39B
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Immatics NV generates 5520% more annual revenue ($41.70M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. IMTX earns a higher WallStSmart Score of 31/100 (F).
IMTX
Avoid31
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 93.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : IMTX
The strongest argument for IMTX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 93.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IMTX
The primary concerns for IMTX are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
IMTX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
IMTX is growing revenue faster at 93.0% — sustainability is the question.
IMTX generates stronger free cash flow (-62M), providing more financial flexibility.
Bottom Line
IMTX scores higher overall (31/100 vs 24/100) and 93.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immatics NV
HEALTHCARE · BIOTECHNOLOGY · USA
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?